Tremelimumab granted Orphan Drug Designation by US FDA for treatment of malignant mesothelioma AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the anti-CTLA-4 monoclonal antibody, tremelimumab, for the treatment of malignant mesothelioma. Mesothelioma is a rare, aggressive cancer that most often affects the lining of the lungs and abdomen. Available treatments for mesothelioma are very limited, particularly for patients with advanced disease. "There is a significant need for new treatment options for patients with mesothelioma because fewer than five percent of patients currently survive beyond five years, even when they receive timely diagnosis and care. Our aim is to rapidly advance the development of tremelimumab as a potential new treatment option for these patients," said Robert Iannone, Senior Vice President, Head of Immuno-oncology, Global Medicines Development at AstraZeneca. The Orphan Drug Designation programme provides orphan status to drugs and biologics, which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US1. Tremelimumab is part of the broad pipeline of immuno-oncology assets being developed by AstraZeneca and its biologics research and development arm, MedImmune, which are designed to harness the body's own immune system to fight cancer. It is a fully human monoclonal antibody, which stimulates the immune system to destroy cancer cells through binding to the protein CTLA-4, expressed on the surface of activated T-lymphocytes. In addition to being investigated as a monotherapy treatment for patients with mesothelioma, tremelimumab is currently being studied in combination with AstraZeneca's anti PD-L1 investigational immunotherapy, MEDI4736, in tumour types including non-small cell lung cancer and head and neck cancer. It is also being studied in combination with Iressa (gefitinib) in EGFR mutated non-small cell lung cancer and with MEDI6469 (a murine OX40 agonist) in solid tumours. 1US Food and Drug Administration. Developing Products for Rare Diseases & Conditions http://www.fda.gov/ForIndustry/DevelopingProd...ions/defau l t.htm Accessed on 31 March 2015 About AstraZeneca in Oncology Oncology is a therapeutic area in which AstraZeneca has deep-rooted heritage. It will be potentially transformational for the company's future, becoming the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one-day eliminate cancer as cause of death. By 2020, we are aiming to bring six new cancer medicines to patients. Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast, and haematological cancers. These are being targeted through four key platforms - immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Vanessa Rhodes +44 20 7604 8037 (UK/Global) Ayesha Bharmal +44 20 7604 8034 (UK/Global) Jacob Lund +46 8 553 260 20 (Sweden) Michele Meixell + 1 302 885 6351 (US) Investor Enquiries Thomas Kudsk Larsen +44 20 7604 8199 mob: +44 7818 524185 Karl Hård +44 20 7604 8123 mob: +44 7789 654364 Eugenia Litz +44 20 7604 8233 mob: +44 7884 735627 Craig Marks +44 20 7 604 8591 mob: +44 7881 615764 Christer Gruvris +44 20 7604 8126 mob: +44 7827 836825 15 April 2015 -ENDS-
Tremelimumab granted Orphan Drug Designation Tremelimumab
Top 10 Most Recent News Articles
Local Bounti Expands: Acquires CEA Facilities
Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...
Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention
Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...
Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights
Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...
Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight
Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....
Continue Reading
Tenax Class Action: Investors Alley Fight for Redress
Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...
Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts
Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...
Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier
Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...
Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution
AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....
Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path
Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...
Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices
Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...
Continue ReadingTop 5 Most Recently Viewed Articles
Vancity Achieves Remarkable Q2 Performance Amid Strategic Shift
Vancity Reports Strong Financial Performance in Q2 Vancity recently showcased its outstanding financial results for the second quarter, demonstrating impressive growth across various metrics and solidifying its commitment to its members. This performance is part of Vancity's transformative vision to enhance member experience while making significant contributions to local...
Continue Reading
Celebrating Courtney Rollings Latham's Exceptional Contributions
Honoring Courtney Rollings Latham, M.Ed, BCBA It brings us great joy to acknowledge Courtney Rollings Latham, M.Ed, BCBA, for achieving the status of a Pinnacle Professional Member in The Inner Circle of Excellence. This recognition showcases her steadfast commitment to enhancing the fields of Behavior Analysis and Special Education. A Passionate Educator and Analyst...
Continue Reading
Savers Value Village, Inc. Reveals Sales Growth and Conference Plans
Savers Value Village, Inc. Reports Preliminary Sales Results BELLEVUE, Wash. – Savers Value Village, Inc. (NYSE: SVV) has released its preliminary net sales for the recent quarter along with its full year results for fiscal 2024. This announcement coincides with the Company’s upcoming participation in the ICR Conference scheduled for mid-January 2025. Sales...
Continue Reading
Empowering Salon Professionals Through Natural Disasters Support
Empowering Professionals in the Face of Adversity Natural disasters can strike unexpectedly, causing chaos and distress. My Salon Suite®, a franchise dedicated to providing beauty, health, and wellness professionals with personal spaces for their businesses, has been at the forefront of community support during such challenging times. As we navigate through the hurricane...
Continue Reading
Major Revenue Surge: POP Culture Group's Impressive FY2025 Results
POP Culture Group Achieves Record Revenue in FY2025 In a remarkable financial breakthrough, POP Culture Group Co., Ltd. (Nasdaq: CPOP) has announced its fiscal year 2025 results, showcasing an incredible revenue surge that exceeded $100 million for the first time. This milestone represents a significant leap, with revenue increasing by 127% compared to the previous fiscal...
Continue Reading